Estrella Immunopharma, Inc.
ESLA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001844417
No open-market purchases or sales by Estrella Immunopharma, Inc. insiders were filed in the last 90 days; 15 institutions reported holding it in 13F filings for Q2 2026, worth $4.99M in total; no superinvestor holds it.
Other share classesESLAW
13F holders, Q1 2026
Institutional positions in Estrella Immunopharma, Inc. as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 16
- +2 vs. Q4 2025
- Shares held
- 5.18M
- +4.63M (+840.2%) vs. Q4 2025
- Total value
- $5.49M
- +$4.63M (+539.1%) vs. Q4 2025
- New holders
- 8
- 3 more added
- Sold out
- 6
- 2 more reduced
1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ESLA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 15 | $4.99M |
| Q1 2026 | 16 | $5.49M |
| Q4 2025 | 15 | $1.56M |
| Q3 2025 | 13 | $878.8K |
| Q2 2025 | 11 | $559.6K |
| Q1 2025 | 11 | $568.4K |
| Q4 2024 | 11 | $341.1K |
| Q3 2024 | 10 | $232.1K |
| Q2 2024 | 7 | $129.2K |
| Q1 2024 | 6 | $165.5K |
| Q4 2023 | 7 | $143.2K |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2026
Shares, value and share of portfolio for each institution holding Estrella Immunopharma, Inc.; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 4,099,000 | $4.34M | 0.14% | +4,099,000 | New |
| Vanguard Capital Management LLC | 382,469 | $405.4K | 0.00% | +382,469 | New |
| Wells Fargo & Company | 264,388 | $280.3K | 0.00% | +264,388 | New |
| Geode Capital Management, LLC | 157,485 | $166.9K | 0.00% | +47,677+43.4% | Added |
| Vanguard Fiduciary Trust Co | 64,921 | $68.8K | 0.00% | +64,921 | New |
| Renaissance Technologies LLC | 62,795 | $66.6K | 0.00% | −59,673−48.7% | Reduced |
| State Street Corp | 43,252 | $45.8K | 0.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 39,890 | $42.3K | 0.00% | +13,420+50.7% | Added |
| Northern Trust Corp | 19,624 | $20.8K | 0.00% | 00.0% | Unchanged |
| US Bancorp | 16,904 | $17.9K | 0.00% | +16,904 | New |
| UBS Group AG | 15,079 | $16.0K | 0.00% | +11,892+373.1% | Added |
| Royal Bank of Canada | 6,600 | $7.00K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 4,859 | $5.15K | 0.00% | +4,859 | New |
| Toronto Dominion Bank | 1,089 | $1.15K | 0.00% | +1,089 | New |
| Wolverine Asset Management LLC | 468 | $496 | 0.00% | +468 | New |
| Morgan Stanley | 1 | $1 | 0.00% | −11,096−100.0% | Reduced |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −64,394−100.0% | Sold out |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −56,236−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −49,472−100.0% | Sold out |
| Quadrature Capital Ltd | 0 | $0 | 0.00% | −27,781−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −10,441−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −10−100.0% | Sold out |
| Vanguard Group Inc | – | – | – | – | Not filed |